Biomarin (BMRN) news
Recent news
Biomarin Pharmaceutical: Barclays raises target price to $114 from $111
AInvest Wire · 22h agoJSE: BYI - Results for the six months ended 31 August 2026 and declaration of cash dividend
AInvest Wire · 2d agoOmron aims to build physical AI platform that uses AI running on industrial computers to operate machinery & robots in coordination - Nikkei
Omron, a Japanese automation and industrial equipment manufacturer, is developing a physical AI platform designed to integrate artificial intelligence with industrial computing systems to coordinate the operation of machinery and robots. According to a report by Nikkei , the initiative aims to…
AInvest Wire · 2d agoBiomarin Pharmaceutical Inc.: Raymond James raises to strong buy from outperform
Raymond James has upgraded its rating for BioMarin Pharmaceutical Inc. (BMRN) to "strong buy" from "outperform," reflecting growing confidence in the company’s strategic direction and financial performance. The move aligns with recent analyst activity, as 24 analysts currently cover the stock, with…
AInvest Wire · 2d agoAlzheimer stocks fell in intraday trading, with Eli Lilly down 4.5%, BioMarin Pharmaceutical down 4.5% and Anavex Life Sciences falling 4.1%.
Alzheimer's-related stocks experienced a decline during intraday trading on October 8, 2026. Eli Lilly and BioMarin Pharmaceutical both fell by 4.5%, while Anavex Life Sciences dropped 4.1%. The downturn reflects broader market sentiment amid ongoing developments in the biotech and healthtech…
AInvest Wire · 6d agoLight Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.